The recent approval of the first gene therapy for children with Duchenne muscular dystrophy (DMD) marks a key moment in the treatment of this debilitating genetic disorder. Much like the breakthrough in spinal muscular atrophy (SMA) treatment with gene therapy in 2019, the development of gene therapies for DMD represents a very important step forward in addressing rare genetic conditions.
With significant advancements in gene-editing technologies, researchers have continued to explore therapeutic options that target the root cause of these disorders. Now, with the approval of Elevidys (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics, there is new hope for improving the lives of children affected by DMD. This is achieved particularly by slowing disease progression and potentially extending life expectancy.
What Is Elevidys and How Does It Work?
Elevidys is a gene therapy designed to address the lack of dystrophin. A protein essential for muscle function, which is either absent or defective in children with DMD. DMD is a progressive neuromuscular disorder that primarily affects boys, leading to severe muscle degeneration and weakness. The absence of dystrophin results in muscle cells breaking down over time, eventually leading to the loss of mobility and a shortened lifespan.
The therapy utilises an adeno-associated virus (AAV) as a vector to deliver a shortened version of the dystrophin gene, known as micro-dystrophin, into the body’s muscle cells. Once inside the cells, this micro-dystrophin helps to stabilise and strengthen muscle fibres, compensating for the missing full-length dystrophin. While it is not a cure, this approach aims to slow the disease’s progression by restoring some degree of muscle function, giving patients the possibility of an improved quality of life.
FDA Approval & Clinical Impact
In June 2023, the U.S. Food and Drug Administration (FDA) initially approved Elevidys for use in children aged 4 through 5 years with a confirmed mutation in the DMD gene. One year later, in June 2024, the approval was expanded. The traditional approval now covers ambulatory patients (those still able to walk) aged 4 and older, and an accelerated approval was granted for non-ambulatory patients within the same age group. These approvals provide an essential treatment option for both early and more advanced stages of the disease.
While Elevidys did not meet its primary endpoint in clinical trials (improving mobility) it demonstrated promising results in secondary endpoints. These included measurable improvements in physical tasks such as time to rise from the floor and walking or running tests. These secondary outcomes provided enough evidence of benefit to support its accelerated approval. This is a pathway the FDA uses for therapies expected to offer clinical benefits for serious conditions with unmet medical needs.
The Challenges of Gene Therapy for DMD
Despite the excitement surrounding Elevidys, gene therapy for DMD is not without its challenges. Firstly, as a one-time treatment, it raises questions about the durability of its effects over the long term. Researchers are still studying how long the benefits of the therapy will last and whether additional treatments may be needed later in life.
Another significant challenge is the body’s immune response to the viral vector used to deliver the gene. The immune system may recognise the AAV as foreign and mount a response against it, which could limit the effectiveness of the treatment or lead to complications. Additionally, the long-term safety of gene therapies is still being evaluated, with potential side effects needing ongoing monitoring in patients who receive Elevidys.
Cost is also a critical consideration. Gene therapies like Elevidys are notoriously expensive, often reaching into the hundreds of thousands of pounds per patient. The high cost is a barrier to widespread adoption and raises questions about accessibility, particularly in healthcare systems that are already under financial strain. Ensuring that such innovative treatments are available to all patients, regardless of economic or geographical factors, will be a significant issue going forward.
Future Implications for Genetic Disorder Treatments
The approval of Elevidys paves the way for further exploration into gene therapies for other genetic disorders. DMD, like many rare conditions, has long had limited treatment options. The success of this therapy could accelerate research into other muscle-wasting diseases and genetic disorders, as well as inspire the development of new delivery methods to improve safety and efficacy.
However, the introduction of therapies like Elevidys also raises broader industry questions about the cost of innovation in gene therapy and how healthcare systems will manage the growing demand for these high-cost, cutting-edge treatments. As more gene therapies become available, there will likely be increased pressure on insurers, governments, and pharmaceutical companies to negotiate prices that make these therapies accessible to all who need them.
The Numbers Behind the Impact
The significance of this development is highlighted by the clinical and industry numbers surrounding Duchenne muscular dystrophy. DMD affects approximately 1 in every 3,500 to 5,000 live male births worldwide, translating to tens of thousands of children globally who could potentially benefit from therapies like Elevidys. The global market for DMD therapies is expected to grow significantly, driven by the rise of innovative treatments such as gene therapies. Industry reports estimate that the global DMD treatment market could exceed £2.5 billion by 2030, driven by ongoing advancements and new therapeutic approvals.
The cost of managing DMD, both in terms of healthcare and quality of life, has historically been high. With the potential of Elevidys to slow the progression of the disease, there could be substantial cost savings in terms of reduced hospitalisations and long-term care needs. Additionally, the success of this therapy could inspire further research into personalised treatments for other rare diseases, potentially revolutionising how we approach genetic disorders on a broader scale.